Lidds AB Logo

Lidds AB

LIDDS | ST

Overview

Corporate Details

ISIN(s):
SE0001958612
LEI:
549300YYW8B918K7UN72
Country:
Sweden
Address:
Box 12040, 112 40 Stockholm
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Lidds AB is a pharmaceutical company that has developed the proprietary NanoZolid® drug delivery technology. This platform is designed for the local, controlled, and sustained release of drugs, aiming to enhance treatment efficacy at the target site while reducing systemic side effects. The technology involves injecting a drug formulation that solidifies into a depot, which releases its therapeutic payload over a prolonged period before being fully absorbed. The company applied this platform to build a pipeline of oncology candidates, including Liproca Depot for prostate cancer and Nanodotax. Lidds' strategy focused on reformulating existing drugs to lower development costs and has pursued partnerships to advance its technology.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Lidds AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lidds AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Lidds AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-02-14 Anders Månsson Other Buy 100,000 140,000.00 SEK
2023-02-10 Matthew Lindon Other Buy 71,428 99,999.20 SEK
2023-02-09 Daniel Lifveredson Other Other 150,000 210,000.00 SEK
2022-12-16 Daniel Lifveredson Other Sell 435,254 826,982.60 SEK
2022-12-16 Daniel Lifveredson Other Buy 435,254 826,982.60 SEK
2022-06-02 Galba Holding AB Other Buy 750,000 4,500,000.00 SEK
2022-03-08 Jan Törnell Other Buy 5,000 32,500.00 SEK
2021-06-30 Nina Herne Other Other 100,000 116,000.00 SEK
2021-06-03 Daniel Lifveredson Other Buy 435,254 4,483,116.20 SEK
2021-05-31 Maria Forss Other Buy 2,300 29,992.00 SEK

Peer Companies

Company Country Ticker View
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom TCF
Theranexus Logo
Biopharma developing drug candidates for rare neurological diseases like Batten disease.
France ALTHX
TME Pharma N.V. Logo
Clinical-stage biotech developing TME-targeting therapies for aggressive cancers.
Germany ALTME
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden TOL
Transgene Logo
Clinical-stage biotech using viral vectors for cancer vaccines and oncolytic viruses.
France TNG
Tvardi Therapeutics Inc. Logo United States of America TVRD
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France ALUCR
Hong Kong N/A
Urteste S.A. Logo
Developing non-invasive urine tests for early detection & monitoring of multiple cancers.
Poland URT
VALIRX PLC Logo
Developing early-stage therapeutics & diagnostics for oncology and women's health.
United Kingdom VAL